Brain-Computer Interface Developer Raised $250 Million
The funding supports new technology designed to record brain activity with less invasive procedures.
Updated on Sept. 24, 2026 in Alzheimer’s
Live Poll
Do you support significant private investment in brain-computer interface technology?
Precision Neuroscience has secured $250 million in new funding, pushing its total valuation beyond $1 billion. This capital will support the company as it develops and refines its less invasive brain-computer interface technology.
Why it matters
The company’s approach seeks to offer an alternative to traditional, more invasive brain-interface methods by using a thin-film device. Investors are backing this strategy as the developer works toward long-term applications for neurological conditions.
Precision Neuroscience has completed over 100 clinical procedures across 18 medical centers using its film-based technology. While the device currently holds FDA clearance for 30 days of use, the company has not yet secured approval for permanent implantation.
The players
Precision Neuroscience
A developer of neurotechnology and brain-computer interfaces based in New York.
Pershing Square
A private investment firm that contributed capital to the company's latest funding round.
The details
The company’s device, known as Layer 7, utilizes a thin film embedded with 1,024 electrodes that is placed directly onto the surface of the brain. This design is engineered to capture neurological signals without the need to penetrate deep into brain tissue like traditional probes. Manufactured in Texas, the device is intended to monitor activity as a foundation for future restorative interventions.
Timeline
Precision Neuroscience was founded in 2021.
The FDA cleared the Layer 7 device for 30 days of use in April 2025.
The company announced its $250 million Series D funding round in September 2026.
Health Landscape
The development of minimally invasive brain-computer interfaces reflects a broader industry shift toward reducing surgical risk while maintaining signal fidelity. This evolution follows a decade of testing deeper probes, positioning thin-film technology as a key alternative in neuro-restoration.
Current applications for this device are limited to short-term, 30-day use under clinical observation. Any patient interested in how these technologies might eventually support brain health should discuss the current state of neuro-restorative research with their neurologist.
The takeaway
This funding round indicates increased market support for less invasive neuro-technologies. Patients should continue to follow official guidance from the FDA regarding the safety and authorized use cases of any brain-interface device.
Further reading
For broader context on how emerging neurological technologies are being applied, visit Alzheimer’s.
Source note: This article includes information reported by The Next Web.
Live Poll
Do you support significant private investment in brain-computer interface technology?
